Interferon Beta-1a (Biogen, Inc.) Due Diligence Report 2026

This Interferon Beta-1a (Biogen, Inc.) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Interferon Beta-1a (Biogen, Inc.) can convert its Interferons profile and Type I IFN Receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Interferon Beta-1a (Biogen, Inc.) (query alias: interferon beta-1a)
Modality / target	Interferons; Type I IFN Receptor; IFNAR agonists, Immunomodulators
Highest global status	Approved
Originator	Biogen, Inc.
Active developers	BIOGEN NETHERLANDS BV, Biogen, Inc., Biogen Australia Pty Ltd.

The MCP disease footprint includes Multiple Sclerosis, Secondary Progressive, Demyelinating Diseases, Multiple sclerosis relapse. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
PACTR202205508723236	Phase 3	Pending	2370	Not disclosed
IRCT20150622022869N9	Phase 3	Complete	176	Not disclosed
NCT05658497	Not Applicable	Recruiting	908	Number of Major Congenital Malformations (MCMs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials

Phase 3; n=1656; evaluation: Positive. Reported fields: Risk of SDMT decline = 18.4 % ; Risk of SDMT decline = 12.7 %

Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014)

Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: CDP = incidence was determined ; CDP = incidence was determined

FDA-Approved Drugs-TYSABRI-CLINICAL STUDIES (II)

Not Applicable; n=1171; evaluation: Positive. Reported fields: Event rate(sustained increase in disability) = 29 % ; Event rate(sustained increase in disability) = 23 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Interferon Beta-1a (Biogen, Inc.) addresses Multiple Sclerosis, Secondary Progressive, Demyelinating Diseases, Multiple sclerosis relapse. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Interferons—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2017-10-23	Eisai and Biogen agreed to co-promote Biogen’s multiple sclerosis (MS) treatments, AVONEX (interferon beta-1a), TYSABRI (natalizumab) and TECFIDERA (dimethyl fumarate) in Japan	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO